Healthy volunteer study sheds light on potential liver disease drug metabolism
NCT ID NCT03159390
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study in 20 healthy adults aged 40-70 examined how the body breaks down ornithine phenylacetate, a compound being explored for liver disease. Researchers used special tracers and collected blood, urine, and muscle samples to track its metabolism. The goal was to understand how the drug is processed, not to test any treatment effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ornithine phenylacetate
- What this could lead to
- If this study clarifies how ornithine phenylacetate is metabolized, it could help design future treatments for liver disease.
- What could go wrong
- This was a small, early-stage study in healthy volunteers, not patients. The results may not apply to people with liver disease, and no therapeutic benefit was tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas A&M University-CTRAL
College Station, Texas, 77843-4253, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test